112 Identification and Validation of Serum MicroRNA Biomarker for Early Detection of Gastric Cancer

from NC (AUC=0.79).High serum ANGPTL2 was significantly associated with advanced T stage (p<0.01),lymph node (p=0.0004) and liver metastasis (p = 0.02) in CRC.Furthermore, Kaplan-Meier curves revealed that high serum ANGPTL2 was significantly associated with poor disease free survival (p=0.01) and overall survival (p=0.03) in CRC.Similarly, serum ANGPTL2 levels in GC patients were also significantly higher compared to NC (p<0.0001), had a promising AUC (0.83) to distinguish GC from NC.In addition, serum ANGPTL2 levels also could discriminate early GC patients (stage I) from NC (AUC=0.80).High ANGPTL2 in serum was significantly associated tumor progression, consequently emerged as an independent predicting recurrence marker (HR=5.05,p=0.0004) and prognostic marker (HR=3.6,p=0.01) in GC.Conclusion: Our study first reports that serum ANGPTL2 was a novel biomarker for diagnosis in patients with GC and CRC.In addition, serum ANGPTL2 levels were significantly associated with tumor progression and prognostic outcomes in both GC and CRC.In particular, serum ANGPTL2 was an independent predictive biomarker of recurrence and prognosis in patients with GC.